Director Karbe Frank purchases 12,500 PHAT shares at $7.93; stock down -56.0% in 90 days amid -$85.6M net loss.
Karbe Frank, a director at Phathom Pharmaceuticals, purchased 12,500 shares at $7.93 on 2024-12-13, increasing his holdings by 28.1% from 44,500 to 57,000 shares. The purchase occurs in a context of significant stock deterioration: PHAT has declined 56.0% over the past 90 days and is trading 58.3% below its 52-week high of $19.50. Fundamentally, the company reported a net loss of $85.6M against quarterly revenue of $16.4M, indicating ongoing unprofitability. Frank's cross-ticker insider track record shows only 2 prior open-market buys with an average 90-day return of -19.7%, suggesting his purchase decisions have not historically preceded price recovery. The timing of this buy—following severe downward momentum and amid continued operating losses—merits investor scrutiny regarding both the company's near-term outlook and the director's own assessment of value.